# TIL Therapy for Patients With Advanced Solid Tumors

> **NCT06107894** · PHASE1 · NOT_YET_RECRUITING · sponsor: **NeogenTC** · enrollment: 12 (estimated)

## Conditions studied

- Advanced Breast Cancer
- Advanced Lung Cancer

## Interventions

- **BIOLOGICAL:** Tumor-infiltrating lymphocytes
- **DRUG:** IL-2

## Key facts

- **NCT ID:** NCT06107894
- **Lead sponsor:** NeogenTC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-01
- **Primary completion:** 2025-09
- **Final completion:** 2026-05
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2023-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06107894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06107894, "TIL Therapy for Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06107894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*